# Bromoantimonates

Bromoantimonates are compounds containing anions composed of bromide (Br$^−$) and antimony (Sb). They can be considered as double bromides, metallohalides or halometallates. They are in the category of halopnictates. Related compounds include the bromobismuthates, iodoantimonates, bromophosphates, and bromoarsenates.

## Some examples of bromoantimonates

Bromoantimonates can have antimony in one of two oxidation states, either +3 or +5. These are designated by bromoantimonate(III) or bromoantimonate(V). Although antimony tribromide is known, SbBr$_5$ on its own does not exist, despite the existence of SbBr−6. Compounds containing both Sb(III) and Sb(V) are mixed valence compounds. The antimony can be linked into chains, (which are called one-dimensional as it is like a line), or in pairs as Sb$_2$ or singly as Sb (which are called zero-dimensional, as the anions are just point-like).
Tetrabromoantimonate(III) (SbBr$_4$$^−$) has single antimony atoms in each anion.
SbBr$_5$$^{2−}$ contains infinite chains of SbBr$_6$ octahedra linked by corners.
Hexabromoantimonate(III) SbBr$_6$$^{3−}$ also exists, forming zero-dimensional compounds.
Nonabromodiantimonate(III) Sb$_2$Br$_9$$^{3−}$ has a pair of octahedra of SbBr$_6$ sharing a face. The angles formed by shared bromine at the antimony are reduced from the theoretical 90° to about 80°.
Hexabromoantimonate(V) SbBr$_6$$^−$ exists in equilibrium with SbBr$_4$$^−$ and Br$_2$ but real +5 oxidation state bromoantimonates exist even if SbBr$_5$ is unstable and does not exist.
Intersecting classes are nonahalogenodiantimon(III)ates. Hexahaloantimonate(III) ions (SbX$_6$$^{3−}$) can include chlorine or iodine as well as bromine.
Related classes include halogeno-oxydiantimon(III)ates, and pentabromothio-diantimonates. Bromo-phenylantimonates(V) (C$_6$H$_5$SbBr$_5$) have a phenyl group substituting for one bromine atom. Chlorobromoantimonates(V) have some chlorine instead of bromine.
The antimonide bromides are distinct as they do not have a bond between antimony and bromine. Tetrabromostibonium(V) contains cations (SbBr+4) rather than anions.

## Preparation

Bromoantimonates can be made using a water solution of antimony tribromide, hydrobromic acid, and an amine. Alternately antimony trioxide can be used. Variants can be made without using water, and heating the antimony tribromide with an amine hydrobromide.

## Some properties

Most of the bromoantimonate salts are yellow or orange.
For SbBr−4 there are absorption bands at 224, 300, 245 and 216 nm. SbBr3−6 has absorption bands centred on 359, 311, and 266 nm.
Many alkylammonium salts are known. These can have different solid phases at different temperatures, as the alkyl group varies in disorder. Those with longer alkyl chains have a greater number of solid state phases.
Methyl ammonium compounds are ferroelectric.
The infrared spectrum includes wavenumbers (ν/c) of 110 to 130 cm$^{−1}$ for the bridging bromine in Sb$_2$Br$_9$ and 135 to 220 cm$^{−1}$ for non-bridging bromine to antimony stretching.
Bond lengths in SbBr$_6$$^−$ are 2.65 and 2.56 Å. In SbBr$_6$$^{3−}$ the lengths are greater, from 2.787 to 2.713 Å.

## Use

Bromoantimonates are researched for use in photovoltaics, X-ray detectors, and LEDs.

## List

| Name (full or part) | Formula | System | Space group | Unit cell (Å) | Volume | Density | Notes | Ref |
| ammonium | [H$_4$N]$_2$SbBr$_6$ | tetragonal | I4$_1$/amd | a=10.66 c=21.52 | | | black; Sb(III) and Sb(V) | |
| ammonium | (NH$_4$)$_3$Sb$_2$Br$_9$ | | | | | | inefficient photovoltaic; soluble in ethanol | |
| ammonium | (NH$_4$)$_7$Sb$_3$Br$_{16}$ | | | | | | | |
| guanidinium | [C(NH$_2$)$_3$]SbBr$_6$ | | | | | | black; Sb(V) | |
| guanidinium | [C(NH$_2$)$_3$]$_3$Sb$_2$Br$_9$ | monoclinic | C2/c | a = 15.695 b = 9.039 c = 18.364 β = 96.94° Z=4 | | | @143K; phase transition 435/450 K | |
| Tris(N,N,N',N'-tetramethylguanidinium) nonabromodiantimonate(III) | [NH$_2$C(N(CH$_3$)$_2$)$_2$]$_3$[Sb$_2$Br$_9$] | triclinic | P1 | a 10.9824 b 12.1782 c 15.0405 α 71.064° β 88.199° γ 85.024° | | | | |
| methylammonium | (CH$_3$NH$_3$)$_3$SbBr$_6$ | monoclinic | P2$_1$/c | a=13.577 b=8.254 c=21.665 β=134.05° Z=4 | | | | |
| methylammonium bromoantimonate(III) | (CH$_3$NH$_3$)$_3$Sb$_2$Br$_9$ | | P3m1 | a=8.188 c=9.927 Z=1 | | 3.049 | yellow | |
| dimethyl ammonium | [(CH$_3$)$_2$NH$_2$]$_3$SbBr$_6$ | | | | | | | |
| tris (dimethylammonium) nonabromodiantimonate(III) | [(CH$_3$)$_2$NH$_2$]$_3$Sb$_2$Br$_9$ | monoclinic | P2$_1$/a | a = 14.612 b = 9.228 c = 10.005 β = 94.91° Z = 2 | | | | |
| | [NH$_2$(CH$_3$)$_2$]$_3$Sb$_2$Br$_9$ | | | | | | | |
| tris(Trimethylammonium) nonabromodiantimonate(III) | [(CH$_3$)$_3$NH]$_3$Sb$_2$Br$_9$ | orthorhomic | | a 11.40 b 10.31 c 12.91 | | | | |
| tetramethylammonium | [NMe$_4$]$_3$[Sb$_2$Br$_9$] | hexagonal | P6$_3$/mmc | a=9.499 c=22.225 Z=2 | | | crimson red | |
| tetramethylammonium | [NMe$_4$]$_3$[Sb$_2$Br$_9$]•Br$_2$ | hexagonal | P6$_3$/mmc | a=9.585 c=22.667 Z=2 | | | | |
| tetramethylammonium | [(CH$_3$)$_4$N]$_3$Sb$_3$Br$_9$•Br$_2$ | hexagonal | P6$_3$/mmc | a=9.5850 c=22.667 Z=2 | | 2.48 | red; yellow-orange when cold | |
| tetramethylammonium | [(CH$_3$)$_4$N]$_3$Sb$_2$Br$_9$•I$_2$ | triclinic | P1 | a=9.4869 b=9.5409 c=22.4906 α=92.058° β=90.933° γ=118.386° Z=2 | 1788.5 | | dark | |
| ethylammonium | (C$_2$H$_5$NH$_3$)$_2$[SbBr$_5$] | orthorhombic | Cmca | a= 7.815 b=22.301 c=18.100 Z=8 | 3154.5 | 2.584 | at 298K; yellow; phase transition at 158.5K; decompose >450K | |
| ethylammonium | (C$_2$H$_5$NH$_3$)$_2$[SbBr$_5$] | orthorhombic | Pbca | a=7.684 b=22.413 c=17.780 Z=8 | 3062.1 | 2.661 | at 90K; yellow | |
| ethylammonium | (C$_2$H$_5$NH$_3$)$_2$[SbBr$_7$] | | | | | | | |
| diethylammonium | ([C$_2$H$_5$]$_2$NH$_2$)$_3$SbBr$_6$ | hexagonal | R3c | a=15.155 c=20.085 Z=6 | | | dissolves in acetone | |
| tetraethylammonium | [(C$_2$H$_5$)$_4$N]$_2$SbBr$_6$ | | | | | | very dark reddish brown | |
| tetraethylammonium | [(C$_2$H$_5$)$_4$N]$_3$Sb$_2$Br$_9$ | hexagonal | P6$_3$22 | a=10.3 c=24.4 Z=2 | 2242 | 2.02 | yellow | |
| tetraethylammonium hexabromoantimonate(V) | [(C$_2$H$_5$)$_4$N]SbBr$_6$ | tetragonal | I4$_1$md | a=8.7008 c=24.797 Z=4 | 1877.3 | 2.59 | dark red-brown | |
| n-propylammonium | (n-C$_3$H$_7$NH$_3$)$_2$SbBr$_5$ | orthorhombic | ? | a =7.884 b=14.516 c=15.913 Z=4 | 1821.1 | 2.33 | 4 phase transitions: 189K, 165/163, 137/154 | |
| di-n-propylammonium | [(n-C$_3$H$_7$)$_2$NH$_2$]$_3$SbBr$_6$ | hexagonal | R3c | a=13.649 c=31.548 Z=6 | | | dissolves in acetone | |
| tris(Tri-n-propylammonium) nonabromodiantimonate(III) | [(n-C$_3$H$_7$)$_3$NH]$_3$Sb$_2$Br$_9$ | orthorhombic | ? | a 12.91 b 14.51 c 20.0 | | | | |
| bis(Isopropylammonium) pentabromoantimonate(III) | [(i-C$_3$H$_7$)$_2$NH$_2$]$_2$SbBr$_5$ | orthorhombic | | a 14.99 b 16.687 c 21.72 | | | | |
| tetrapropylammonium | [(C$_3$H$_7$)$_4$N][SbBr$_4$] | orthorhombic | Pbca | a=15.566 b=13.822 c=19.574 Z=8 | 4211.5 | | yellow | |
| isopropylammonium | [(CH$_3$)$_2$CHNH$_3$]$_2$SbBr$_5$ | orthorhombic | | a=12.013 b =12.134 c=12.525 | | | phase transition at 171K, 180 K | |
| isopropylammonium | [(CH$_3$)$_2$CHNH$_3$]$_2$SbBr$_5$ | monoclinic | | | | | | |
| tris(N-ethyl-N,N-dipropylpropan-1-aminium) tetrakis(μ-bromo)-octabromo-tri-antimony | (Et(n-Pr)$_3$N)$_3$[Sb$_3$Br$_{12}$] | triclinic | P1 | a 10.6469 b 14.8847 c 18.3714 α 86.082° β 85.502° γ 84.116° | | | | |
| isobutyl | (i-C$_4$H$_9$NH$_3$)$_2$SbBr$_5$ | | | | | | | |
| ethanediammonium | [NH$_3$(CH$_2$)$_2$NH$_3$]$_5$(Sb$_2$Br$_{11}$)$_2$·4H$_2$O | monoclinic | P2$_1$/a | a = 14.346 b = 13.206 c = 17.027 β = 113.05° Z = 2 | | 2.941 | | |
| N,N,N',N'-tetramethylethylendiammonium [tetrabromidoantimonate(III)-μ-bromido] hemihydrate | (C$_6$H$_{18}$N$_2$)$_2$[Sb$_2$Br$_{10}$]·H$_2$O | orthorhombic | Pbca | a = 18.0860 b = 19.1755 c = 19.4619 Z=8 | 6749.5 | 2.553 | yellow | |
| anilinium | (C$_6$H$_5$NH$_3$)$_2$SbBr$_5$ | orthorhombic | Pbca | a = 19.704 b = 7.914 c = 25.556, Z = 8 | 3985 | 2.365 | yellow green; insoluble water | |
| dihydrazinium pentabromoantimonite | (N$_2$H$_5$)$_2$SbBr$_5$ | | | | | | yellow | |
| Trihydrazinium nonabromodiantimonite | (N$_2$H$_5$)$_3$Sb$_2$Br$_9$ | | | | | | yellow | |
| Undecahydrazinium heptadecabromodiantimonite | (N$_2$H$_5$)$_{11}$Sb$_2$Br$_{17}$ | | | | | | yellow; melt 165° | |
| Decahydrazinium nonadecabromotriantimonite | (N$_2$H$_5$)$_{10}$Sb$_3$Br$_{19}$ | | | | | | yellow | |
| triazolinium | (C$_2$H$_4$N$_3$)$_2$[SbBr$_5$]·(C$_2$H$_4$N$_3$)Br | orthorhombic | P2$_1$2$_1$2$_1$ | a=8.6087 b=11.7985 c=20.5457 | | | | |
| 1,2,4-triazolium | (C$_2$N$_3$H$_4$)$_3$[SbBr$_6$] | tetragonal | P4$_2$/m | a=11.149 c=8.318 Z=2 | 1033.9 | 2.606 | @320K | |
| 1,2,4-triazolium | (C$_2$N$_3$H$_4$)$_3$[SbBr$_6$] | monoclinic | | a=15.699 b=16.294 c=15.018 β = 90.41 Z=8 | 4097 | 2.631 | @293K | |
| allylammonium | (C$_3$H$_5$NH$_3$)$_3$SbBr$_6$ | monoclinic | C2/m | | | | 4 phases | |
| butylammonium | [n-C$_4$H$_9$NH$_3$]$_2$•[SbBr$_5$] | orthorhombic | Pnma | a=16.845 b=54.899 c=15.697 | | | 340K deep yellow; 3 phases | |
| butylammonium | [n-C$_4$H$_9$NH$_3$]$_2$•[SbBr$_5$] | monoclinic | P2/m | a=15.597, b=62.854, c=16.771 β=92.05° | | | 300K | |
| tris(n-Butylammonium) hexabromo-antimony(III) | [n-C$_4$H$_9$NH$_3$]$_3$•[SbBr$_6$] | | | a 11.47 b 15.07 c 18.57 | | | | |
| di-n-butylammonium | [(n-C$_4$H$_9$)$_2$NH$_2$]$_3$•[SbBr$_6$] | monoclinic | P2$_1$/c | a 13.03 b 13.51 c 18.94 β 94.0° | | | | |
| tetra-n-butylammonium hexa-bromoantimonate(V) | [(n-C$_4$H$_9$)$_4$N]•[SbBr$_6$] | | | | | | | |
| pentylammonium | [n-C$_5$H$_{11}$NH$_3$]$_2$•[SbBr$_5$] | orthorhombic | Pna2$_1$ | a=17.0105 b=32.875 c=7.8882 | | | 298K; 3 phases transitions at 388K 224K | |
| pentylammonium | [n-C$_5$H$_{11}$NH$_3$]$_2$•[SbBr$_5$] | orthorhombic | P2$_1$2$_1$2$_1$ | a=16.9234 b=32.3689 c=7.7418 | | | 86K | |
| 2,2-difluoroethylammonium | [C$_2$H$_6$F$_2$N]$_3$SbBr$_6$ | monoclinic | P$_1$2$_1$/n$_1$ | a=8.0145 b=12.1192 c=21.2967 β=91.686 Z=4 | 2067.6 | 2.722 | yellow | |
| N-ethyl-1,3-propanediammonium | [C$_5$N$_2$H$_{16}$]$_2$SbBr$_5$ | monoclinic | P2$_1$/c | a=21.426 b=7.889 c=19.96 β=116.79° Z=8 | 3012 | | | |
| N-ethyl-1,3-propanediammonium | [C$_5$N$_2$H$_{16}$]$_2$SbBr$_5$ | orthorhombic | Pnma | a=19.23 b=7.894 c=10.118 Z=4 | 1536 | | yellow | |
| bis(N,N-diethylethylendiammonium) decabromodiantimoinate(III) | [C$_6$H$_{18}$N$_2$]$_2$Sb$_2$Br$_{10}$ | monoclinic | P2$_1$/c | a = 10.7309 b = 10.5842 c = 14.5551 β = 96.962° Z = 4. | | | yellow | |
| 1,5-pentanediammonium pentabromoantimonate (III) | [NH$_3$(CH$_2$)$_5$NH$_3$]SbBr$_5$ | orthorhombic | P2$_1$2$_1$2$_1$ | a 7.964 b 13.9424 c 14.065 | | | @293K | |
| 1,5-pentanediammonium pentabromoantimonate (III) | [NH$_3$(CH$_2$)$_5$NH$_3$]SbBr$_5$ | orthorhombic | Pnma | a 14.04 b 8.04 c 13.97 | | | @393K | |
| Ethyldimethylphenylammonium | [EtMe$_2$PhN]$_3$[Sb$_2$Br$_9$] | orthorhombic | Pnma | a = 35.620 b = 9.954 c = 12.761 Z = 4 | | | | |
| Tris(N,N-dimethylanilinium) tri--bromido-bis[tribromidoantimonate(III)] | (C$_8$H$_{12}$N)$_3$[Sb$_2$Br$_9$] | triclinic | P1 | a 9.7857(b 13.7658(c 17.0297(α 66.581( β 78.689( γ 72.601( Z=2 | | | | |
| | [CH$_3$SC(NH$_2$)$_2$]$_2$SbBr$_5$ | | | 11.4258 b=8.9079 c=17.3627 β=92.225 Z=4 | 1765.8 | 2.647 | | |
| cyclopropylammonium | [C$_3$H$_8$N]$_2$SbBr$_5$ | monoclinic | P2$_1$/c | a=11.8937 b=19.0986 c=7.8047 β = 108.908° | 1168.0 | 2.525 | 270K | |
| cyclopropylammonium | [C$_3$H$_8$N]$_2$SbBr$_5$ | orthorhombic | Pnca | a=22.5314 b=18.9885 c=7.8845 Z=8 | 2336.0 | 2.511 | 300K | |
| cyclopropylammonium | [C$_3$H$_8$N]$_2$SbBr$_5$ | orthorhombic | Bbcm | a=22.4485 b=18.9653 c=7.9488 Z=8 | 2256 | 2.503 | 325K; band gap 2.41 eV; phase changes at 290 K and = 315 K | |
| Benzeneethanammonium | (C$_8$NH$_{12}$)$_2$SbBr$_5$ | | | | | | yellow | |
| phenylmethylammonium | (C$_6$H$_5$CH$_2$NH$_3$)$_3$SbBr$_6$ | monoclinic | P2$_1$/c | a 15.2246 b 8.0632 c 24.3042 β 100.005° Z=4 | 2938.2 | 2.093 | yellow | |
| (R)-(−)-1-cyclohexylethylammonium | (R-CHEAH)Sb$_3$Br$_{10}$ | monoclinic | P2$_1$ | a=12.76938 b=30.1777 c=13.2336 β=90.818 | | | | |
| Pyrrolidinium | [C$_4$H$_9$N]$_2$SbBr$_8$ | monoclinic | | a=31.4 b=9.71 c=15.0 β=99.0° Z=8 | 4517 | 2.50 | black | |
| 2-Pyrolidonium | [C$_4$H$_6$ONH]$_2$SbBr$_8$ | | | | | | black; orange red when cold | |
| N-methylpyrrolidinium | [C$_4$H$_9$NCH$_3$]$_3$Sb$_2$Br$_9$ | trigonal | R3c | a=15.6943 c=15.6943 Z=6 | 5018.8 | 2.424 | yellow @293K | |
| N-methylpyrrolidinium | [C$_4$H$_9$NCH$_3$]$_3$Sb$_2$Br$_9$ | trigonal | R3c | a=15.9951 c=23.1124 Z=5 | 5120.9 | 2.376 | @335K | |
| N-methylpiperidine | (C$_6$H$_{14}$N)$_3$Sb$_3$Br$_{12}$ | monoclinic | P2$_1$/n | a=10.9372 b=21.928 c=17.598 β=90.796° Z=4 | 4219.5 | | | |
| Piperidinium | [C$_5$H$_{11}$N]$_2$SbBr$_8$ | monoclinic | | a=28.8 b=19.8 c=18.7 β=116.28 Z=16 | 9561 | 2.58 | black | |
| Piperazine-1,4-diium | (C$_4$H$_{12}$N$_2$)[SbBr$_5$]·H$_2$O | monoclinic | P2$_1$/n | a=9.9162 b=14.4090 c=10.3898 β=99.432 Z=4 | 1464.45 | 2.846 | | |
| Morpholinium | [NH$_2$(C$_2$H$_4$)$_2$O]SbBr$_4$ | orthorhombic | Pbca | a=12.273 b=8.397 c=23.276 Z=8 | 2399 | 2.933 | yellow | |
| Morpholinium | [NH$_2$(C$_2$H$_4$)$_2$O]$_2$[SbBr$_5$] | orthorhombic | P2$_1$2$_1$2$_1$ | a 9.274 b 10.325 c 18.472 Z=4 | 1768.8 | 2.620 | yellow; piezoelectric | |
| Morpholinium | [C$_4$H$_9$ONH]$_2$SbBr$_8$ | orthorhombic | Pna2$_1$ | a=28.01 b=8.31 c=10.02 Z=4 | 2332 | 2.64 | black; red when cold | |
| Pyridinium | (C$_5$H$_5$NH)SbBr$_4$ | triclinic | P1 | | | | @116K | |
| Pyridinium | (C$_5$H$_5$NH)SbBr$_4$ | monoclinic | C2/c | a=11.825 b=13.048 c=7.798 β=93.87° Z=4 | | 2.922 | @297K | |
| Pyridinium | (C$_5$H$_5$NH)$_6$Sb$^{III}$Sb$^V$$_3$Br$_{24}$ | orthorhombic | CmC21 | a=17.51 b=23.77 c=16.46 Z=4 | 6851 | 2.80 | black | |
| benzylammonium | (C$_6$H$_5$CH$_2$NH$_3$)$_2$SbBr$_5$ | monoclinic | P2$_1$/a | a=8.0254 b=19.5087 c=14.5079 β=107.451 Z=4 | 2166.89 | 2.261 | yellow | |
| 1-methylpyridinium | (1−CH$_3$C$_5$H$_4$NH)SbBr$_4$ | monoclinic | P2$_1$/c | a=12.73 b=13.54 c=7.59 β=107.3 Z=4 | 1250 | 2.85 | pale yellow | |
| bis(1-methylpyridin-1-ium) hexabromo-antimony tribromide | (1−CH$_3$C$_5$H$_4$NH)$_2$SbBr$_6$•Br$_3$ | triclinic | P1 | a 7.4567 b 9.4488 c 9.6777 α 68.629° β 89.848° γ 73.002° | 1029.2 | | | (1) |
| 2-methylpyridinium | (2−CH$_3$C$_5$H$_4$NH)SbBr$_4$ | monoclinic | P2$_1$/c | a=12.84 b=13.31 c=7.65 β=106.6 Z=4 | 1252 | 2.84 | pale yellow | |
| 3-methylpyridinium | (3−CH$_3$C$_5$H$_4$NH)SbBr$_4$ | monoclinic | P2$_1$/c | a=12.51 b=13.64 c=7.72 β=106.9 Z=4 | 1260 | 2.76 | pale yellow | |
| bis(2-bromo-5-methylpyridinium) hexabromoantimonate tribromide | (2-Br-5-MePy)$_2$[SbBr$_6$](Br$_3$) | monoclinic | Im | a 8.4041 b 13.341 c 12.237 β 95.731° | | | | |
| 3-carboxylpyridinium | (3−COOHC$_5$H$_4$NH)$_2$SbBr$_5$ | monoclinic | C2/c | a=14.10 b=19.43 c=8.01 β=98.6° Z=4 | 2169 | 2.36 | lemon yellow | |
| 4-methylpyridinium | (4−CH$_3$C$_5$H$_4$NH)SbBr$_4$ | monoclinic | P2$_1$/c | a 12.011 b 13.581 c 7.7637 β 90.341° | | | | |
| 4-methylpyridinium | (4−CH$_3$C$_5$H$_4$NH)$_2$SbBr$_5$ | triclinic | P1 | a=10.66 b=10.86 c=9.30 α=108.8° β=97.7° γ=99.2° Z=2 | 985 | 2.39 | yellow needles | |
| 4-methylpyridinium | (4−CH$_3$C$_5$H$_4$NH)$_3$Sb$_2$Br$_9$•I$_2$ | monoclinic | P2$_1$ | a=8.3290 b=23.5510 c=9.4722 β=104.388 Z=2 | 1799.7 | | | |
| 4-methylpyridinium | (4−CH$_3$C$_5$H$_4$NH)$_2$SbBr$_5$•I$_2$ | monoclinic | P2$_1$/n | a=7.5955 b=14.6757 c=9.5902 β=91.607 Z=2 | 2182.85 | | | |
| 4-methylpyridinium | (4-C$_6$H$_7$NH)$_2$Sb$^V$Br$_9$ | monoclinic | C2/m | a=18.39 b=7.440 c=9.84 β=113.14° | | 2.760 | red | |
| α-picolinium | (2−CH$_3$C$_5$H$_4$NH)$_2$SbBr$_9$ | triclinic | P1 | a 9.249 b 9.750 c 7.645 α 90.07° β 107.46° γ 70.52° Z=2 | | 2.77 | black; orange at −174° | |
| β-picolinium | (3−CH$_3$C$_5$H$_4$NH)$_2$SbBr$_9$ | monoclinic | | Z=2 | | 2.74 | black; orange at −174° | |
| γ-picolinium | (4−CH$_3$C$_5$H$_4$NH)$_2$SbBr$_9$ | monoclinic | | Z=2 | | 2.77 | black; red at −174° | |
| 1-fluoropyridinium | (1-FPy)$_3$[Sb$_2$Br$_9$] | monoclinic | C2/c | a=21.85 b=21.15 c=13.85 β=104.6° Z=8 | 6179 | 2.70 | deep yellow | |
| 1-bromopyridinium | ? | monoclinic | C2/c | a=11.83 b=13.03 c=7.70 β=93.9° | 1183 | 2.4 | light orange | |
| 2-chloropyridinium | (2-ClPyH)$_2$SbBr$_5$ | monoclinic | P2$_1$/a | a=10.64 b=15.87 c=5.88 β=105.3° Z=2 | 957 | 2.60 | orange | |
| 2-chloropyridinium | (2-ClPyH)SbBr$_6$ | monoclinic | P2$_1$/c | a=13.0770 b=7.3498 c=16.5301 β=112.117° | | | Sb(V) | |
| 2-bromopyridinium | (2-BrPyH)$_2$SbBr$_5$ | monoclinic | P2$_1$/a | a=10.53 b=16.17 c=5.89 β=104.8° Z=2 | 989 | 2.82 | red | |
| 2-bromopyridinium | (2-BrPyH)SbBr$_6$ | monoclinic | P2$_1$/c | a=13.111 b=7.3787 c=16.555 β=111.179° | | | Sb(V) | |
| bis(2-iodopyridinium) hexabromoantimonate tribromide | (2-IPyH)$_2$[SbBr$_6$](Br$_3$) | monoclinic | P2$_1$/n | a 8.1800 b 12.9394 c 12.5865 β 105.412° | | | | |
| 3-chloropyridinium | (3-ClPyH)SbBr$_6$ | orthorhombic | Pca2$_1$ | a=16.6414 b=7.3471 c=24.2543 Z=8 | 2965.5 | | cherry-red | |
| 3-bromopyridinium | (3-BrPyH)$_2$SbBr$_5$ | monoclinic | P2$_1$/c | a=18.37 b=11.98 c=9.35 β=102.5° Z=4 | 2009 | 2.77 | pale yellow | |
| 3-bromopyridinium | (3-BrPyH)SbBr$_6$ | orthorhombic | Pca2$_1$ | | | | cherry-red | |
| 3-iodopyridinium | (3-IPyH)$_2$SbBr$_5$ | monoclinic | P2$_1$/c | a=17.99 b=12.31 c=9.35 β=91.5° Z=4 | 2070 | 2.99 | pale yellow | |
| 4-bromopyridinium pentabromoantimonate(III) | (4-BrC$_5$H$_4$NH)$_2$SbBr$_5$ | triclinic | P1 | a = 9.186 b = 10.622 c = 10.703 α = 99.665° β = 97.393° γ = 108.539° Z = 2 | | | | |
| bis(4-bromopyridinium) hexabromoantimonate tribromide | (4-BrPyH)$_2$[SbBr$_6$](Br$_3$) | monoclinic | P2$_1$/c | a 7.3255 b 20.667 c 16.5665 β 95.627° | | | | |
| 2,6-dichloropyridinium | (2,6-ClPyH)[SbBr$_4$] | monoclinic | P2/m | a=10.45 b=10.76 c=13.45 β=110.2 Z=4 | 1491 | 2.76 | pale yellow | |
| 2,6-dibromopyridinium | (2,6-BrPyH)$_3$[SbBr$_6$](Br$_3$) · 2H$_2$O | monoclinic | C2/c | a=32.8242 b=9.6155 c=14.7877 β=101.732° | | | | |
| 3,5-dichloropyridinium | (3,5-ClPyH)$_2$[SbBr$_5$] | orthorhombic | Pbca | a=21,77 b=8.14 c=24.38 Z=8 | 4320 | 2.52 | deep yellow | |
| N-ethylpyridinium | EtPySbBr$_6$ | | | | | | | |
| N-propylpyridinium | 1-n-PrPySbBr$_6$ | monoclinic | P2$_1$/n | a=7.3687 b=16.4706 c=13.8620 β=97.054 Z=4 | 1669.65 | | | (1) |
| N-butylpyridinium | 1-n=BuPySbBr$_6$ | orthorhombic | P2$_1$2$_1$2$_1$ | a=7.4277 b=14.1293 c=16.7699 Z=4 | 1760.0 | | | (2) |
| 2-aminopyridinium | [2-NH$_2$C$_5$H$_4$NH][SbBr$_4$] | monoclinic | P2$_1$/c | a 12.484 b 13.106 c 7.492 β 105.84° Z=4 | 1179.1 | 3.022 | @100K phase transition at 396/412K | |
| 4-aminopyridinium | (4-NH$_2$C$_5$H$_4$NH)SbBr$_4$ | monoclinic | P2$_1$/c | a 11.548 b 14.029 c 7.432 β 93.19° | | | @220K | |
| tetrakis(2,2'-bipyridin-1-ium) tetrakis(μ-bromo)-hexadecabromo-tetra-antimony | (2,2′-bipyH)$_4$[Sb$_4$Br$_{20}$] | monoclinic | P2$_1$/c | a 14.5026 b 14.6945 c 16.5497 β 109.991° | | | | |
| bis(pyridinium)ethane | (PyC$_2$){[SbBr$_6$](Br$_3$)} | triclinic | P1 | a=7.3269 b=9.1941 c=9.7994 α=64.474 β=80.207 γ=86.244 Z=1 | 586.99 | | cherry-red | |
| 1,1′-(1,2-ethanediyl)bis(pyridine) | PyC$_2$$^{2+}$SbBr$_5$ | triclinic | P1 | a 10.1060 b 10.2956 c 11.1394 α 105.030° β 101.709° γ 117.233° | | | | |
| 1,1′-(1,2-ethanediyl)bis(3,5-dimethylpyridine) | 3,5-MePyC$_2$$^{2+}$SbBr$_5$ | monoclinic | P2/n | a 6.2898 b 8.7454 c 20.408 β 90.438° | | | | |
| 1,1′-(1,2-ethanediyl)bis(pyridine) | (C$_2$Py)$_2$[Sb$_2$Br$_{10}$] | triclinic | P1 | a 6.1343 b 9.2857 c 17.2041 α 90.331° β 100.259° γ 99.912° | | | | |
| 1,1′-(1,2-ethanediyl)bis(pyridine) | (C$_2$Py)$_2$[Sb$_2$Br$_{10}$] | monoclinic | C2/c | a 19.6880 b 10.0152 c 20.8410 β 111.104° | | | | |
| 1,1′-(1,2-ethanediyl)bis(3,5-dimethylpyridine) | (3,5-MePy){[SbBr$_4$]} | monoclinic | P2$_1$/n | a 20.5536 b 7.2974 c 21.2510 β 117.694° | | | | |
| bis(pyridinium)propane | (PyC$_3$)$_2$[Sb$_2$Br$_9$][SbBr$_6$] | orthorhombic | Pmmm | a=20.3785 b=15.5018 c=7.4618 Z=2 | 2357.2 | | mixed III V valence | |
| bis(pyridinium)butane | (PyC$_4$){[SbBr$_6$](Br$_3$)} | triclinic | P1 | a=7.8627 b=9.1285 c=10.1514 α=68.392° β=89.669° γ=72.048° Z=1 | 639.63 | | | |
| 4-ethylpyridinium | (4−CH$_3$CH$_2$C$_5$H$_4$NH)$_3$Sb$_2$Br$_{14}$ | orthorhombic | Pna2$_1$ | Z=4 | | 2.55 | black; orange-red at −174° | |
| 1,1′-(propane-1,3-diyl)bis(4-methylpyridin)-1-ium | (4-MePyC$_3$)$_2$[SbBr$_6$]$_2$[Br$_5$]$_2$ | monoclinic | P2$_1$/n | a=7.7157 b=16.1786 c=24.292 β=96.972° | | | Sb(V) | |
| propanediyl-bis(3-methylpyridinium) | (3-MePyC$_3$)$_3$[Sb4Br16] | monoclinic | P2$_1$/n | a 11.6777 b 42.282 c 16.5504 β 95.618° | | | | |
| 1,1'-(ethane-1,2-diyl)bis(3-methylpyridin-1-ium) | (3-MePyC$_2$)$_3$[Sb$_2$Br$_9$]$_2$ | triclinic | P1 | a 10.6368 b 10.8059 c 15.4810 α 76.034° β 81.735° γ 83.387° | | | | |
| bis(1,1'-(butane-1,4-diyl)bis(3-methylpyridin-1-ium)) hexakis(μ-bromo)-decabromo-tetra-antimony(iii) | (3-MePyC$_4$)$_3$[Sb4Br$_{16}$] | monoclinic | P2$_1$/n | a 14.2410 b 11.2731 c 19.0662 β 110.674° | | | | |
| 4,4'-dimethyl-1,1'-butanediylbis(pyridinium) | (4-MePyC$_4$)[Sb$_2$Br$_8$] | monoclinic | P 2/c | a 26.313 b 6.4010 c 17.9886 β 109.026° | | | | |
| 4,4'-dimethyl-1,1'-butanediylbis(pyridinium) | (4-MePyC$_4$)$_2$[Sb$_4$Br$_{16}$] | monoclinic | P2$_1$/n | a 11.4661 b 19.7236 c 12.5217 β 92.726° | | | | |
| 1,3,4-trimethylpyridin-1-ium | 1,3,4-MePy[SbBr$_6$] | triclinic | P1 | a 8.3195 b 8.9921 c 12.3360 α 86.146° β 76.520° γ 71.872° | | | Sb(V) | |
| 1,4-dimethylpyridin-1-ium | 1,4-MePy[SbBr$_6$] | triclinic | P1 | a 7.6803 b 8.5900 c 12.6261 α 75.226° β 88.079° γ 79.872° | | | Sb(V) | |
| 1,2-dimethylpyridinium | (1,2-MePy)$_2$[SbBr$_6$](Br$_3$) | monoclinic | P2$_1$/n | a=7.3284 b=10.5875 c=16.7538 β=96.005° | | | Sb(V) | |
| 1,3-dimethylpyridinium | (1,3-MePy)$_2$[SbBr$_6$](Br$_3$) | triclinic | P1 | a 7.2611 b 9.086 c 11.1895 α 67.617° β 87.457° γ 72.16° | | | | (5) |
| 2,4-dimethylpyridinium | ? | orthorhombic | Pmmn | a=12.06 b=12.97 c=11.49 | 1797 | 2.2 | yellow | |
| 2,6-dimethylpyridinium | (2,6-MePy)$_3$[Sb$_2$Br$_9$] | monoclinic | P2$_1$/c | a=12.10 b=15.56 c=21.27 β=115.7 Z=4° | 3629 | 2.36 | pale yellow | |
| 1-ethyl-3-methylpyridinium | (1-Et-3-MePy)$_2$[SbBr$_6$](Br$_3$) | triclinic | P1 | a 7.2472 b 9.4088 c 11.5541 α 69.263° β 81.162° γ 71.303° | | | | |
| 4-ethyl-1-methylpyridinium | (4-Et-1-MePy)$_2$[SbBr$_6$](Br$_3$) | monoclinic | P2$_1$/n | a 8.4645 b 13.0802 c 13.1574 β 105.702° | | | | |
| bis(2,6-dimethylpyridin-1-ium) hexabromo-antimony pentabromide | (2,6-MePy)$_2$[SbBr$_6$](Br$_5$) | monoclinic | P2$_1$/c | a 7.4584 b 18.0860 c 21.626 β 93.607° Z=4 | 2911.4 | | | (3) |
| bis(1,3,5-trimethylpyridin-1-ium) hexabromo-antimony tribromide | (1,3,5-MePy)$_2$[SbBr$_6$](Br$_3$) | triclinic | P1 | a 8.1964 b 8.2015 c 12.5202 α 92.883° β 103.923° γ 115.467° Z=4 | 1085.3 | | 100K | (4) |
| 2,4,6-trimethylpyridinium | (2,4,6-MePy)$_3$[Sb$_2$Br$_9$] | monoclinic | P2$_1$/n | a=10.36 b=42.36 c=9.09 β=100.2° Z=4 | 3926 | 2.25 | yellow-tan | |
| 2,4,6-trimethylpyridinium | (2,4,6-MePy)[SbBr]•0.5Br$_2$ | monoclinic | P2$_1$/n | a 10.4938 b 13.6198 c 12.8807 β 90.339° Z=4 | 1840.9 | | 100k | (5) |
| bis(3,5-dimethylpyridin-1-ium) hexabromo-antimony tribromide | (3,5--MePy)$_2$[SbBr$_6$](Br$_3$) | orthorhombic | Pnnm | a 17.1097 b 10.4401 c 7.3438 Z=2 | 1311.8 | | | (2) |
| bis(1-ethyl-3-methylpyridinium) hexabromoantimonate tribromide | (1-Et-3-MePy)$_2$[SbBr$_6$](Br$_3$) | triclinic | P1 | a 7.2472 b 9.4088 c 11.5541 α 69.263° β 81.162° γ 71.303° | | | | |
| 1-ethyl-4-methylpyridin-1-ium | (1-Et-4-MePy)$_2$[SbBr$_6$](Br$_3$) | monoclinic | P2$_1$/n | a=11.4927 b=7.3613 c=16.9266 β=100.782° | | | Sb(V) | |
| 1-ethyl-2-methylpyridin-1-ium | (1-Et-2-MePy)$_2$[SbBr$_6$](Br$_3$) | monoclinic | P2$_1$/n | a=8.3421 b=13.196 c=13.183 β=105.40° | | | Sb(V) | |
| 1-ethyl-2,6-dimethylpyridin-1-ium hexabromoantimonate | (1-Et-2,6-MePy)[SbBr$_6$] | monoclinic | P2$_1$/c | a 9.9470 b 11.5017 c 16.4632 β 107.201° | | | | |
| | (PyC$_3$)$_3$[Sb$_2$Br$_9$]$_2$ | | | | | | | |
| | (PyC$_4$)[Sb$_2$Br$_8$] | | | | | | | |
| | (PyC$_5$)$_2$[α-Sb$_4$Br$_{16}$] | | | | | | | |
| | (PyC$_6$)$_2$[Sb$_2$Br$_{10}$] | | | | | | | |
| | (4-MePyC$_2$)$_2$[Sb$_2$Br$_{10}$] | | | | | | | |
| | (4‑MePyC$_3$)$_2$[α-Sb$_4$Br$_{16}$] | | | | | | | |
| | (4-MePyC$_5$)$_2$[α-Sb$_4$Br$_{16}$] | | | | | | | |
| 1-benzylpyridin-1-ium hexabromoantimonate | C$_6$H$_5$CH$_2$PySbBr$_6$ | orthorhombic | Pnma | a=12.6594 b=17.3414 c=8.6389 Z=4 | 1896.5 | | | (6) |
| bis(1-benzyl-2-methylpyridinium) hexabromoantimonate tribromide | (CH$_3$-C$_6$H$_5$CH$_2$Py)$_2$SbBr$_6$(Br$_3$) | triclinic | P1 | a 8.9834 b 10.2599 c 10.3601 α 94.223° β 102.737° γ 111.846° | | | | (7) |
| bis(1-(4-bromobenzyl)pyridinium) hexabromoantimonate tribromide | (BrC$_6$H$_4$CH$_2$Py)$_2$SbBr$_6$(Br$_3$) | monoclinic | P2$_1$/c | a 8.6483 b 15.1885 c 13.3520 β 98.887° | | | | |
| 2,2'-bipyridinium pentabromoantimonate (III) | (2,2'-C$_{10}$H$_8$N$_2$H$_2$)SbBr$_5$ | monoclinic | P2$_1$/c | a = 14.575 b = 14.726 c = 16.775 β = 110.34° Z = 8 | | | | |
| 4,4'-bipyridinium pentabromoantimonate (III) | (4,4'-C$_{10}$H$_8$N$_2$H$_2$)SbBr$_5$ | triclinic | P1 | a = 11.28.7 b = 10.121 c = 8.548 α = 98.94° β = 101.06° γ = 113.57° Z = 2 | | | | |
| imidazolium | (C$_3$N$_2$H$_5$)$_3$SbBr$_6$.H$_2$O | monoclinic | P2$_1$/c | a=8.9137 b=19.2032 c=12.7984 β=90.650° | | | | |
| imidazolium | (C$_3$N$_2$H$_5$)$_5$Sb$_2$Br$_{11}$ | monoclinic | P2$_1$/n | a 9.1399 b 15.150 c 13.969 β 96.19° | | | ferroelectric Curie Point 145K; 4 phases | |
| thiazolium | (C$_3$H$_4$NS)$_6$Sb$_4$Br$_{18}$·2H$_2$O | triclinic | P1 | a 11.060 b 11.465 c 12.957 α 116.21° β 100.71° γ 98.87° | | | | |
| quinolinium | | monoclinic | Cc | a=15.28 b=14.04 c=7.44 β =118.3 Z=4 | 1405 | 2.70 | light yellow | |
| quinolinium | (C$_9$H$_7$NH)$_2$SbBr$_9$ | monoclinic | P2$_1$/n | as=7.518 b=11.316 c=16.351 β =97.41 Z=2 | | | Sb(V) | |
| 3-Bromoquinolinium | (3-BrQuinH)$_4$[Sb$_2$Br$_{10}$] | monoclinic | C2/c | a 15.3947 b 13.7967 c 22.8880 β 92.039° | | | | 2 |
| 5-Bromoquinolinium | (5-BrQuinH)$_2$[SbBr$_5$] | monoclinic | C2/c | a 23.8681 b 12.2567 c 8.6474 β 106.128° | | | | 3 |
| 3-Bromo-1-methylquinolinium | (1-Me-3-BrQuin)$_3$[Sb$_3$Br$_{12}$] | triclinic | P1 | a 9.8582 b 11.7183 c 21.6576, α 98.981° β 96.402° γ 92.371° | | | | 5 |
| isoquinolinium | isoquinHSbBr$_4$ | monoclinic | P2$_1$/a | a=13.11 b=14.14 c=7.57 β=91.4 Z=4 | 1403 | 2.71 | light tan | |
| N-methyl quinolinium | (N-MeQuin)$_2${[SbBr$_6$](Br$_3$)} | triclinic | P1 | a=8.0902 b=8.5656 c=11.6475 𝛼 = 68.901° β = 79.204° 𝛾 = 77.120° Z=1 | 728.98 | | | |
| N-methyl isoquinolinium | (N-MeIsoquin)$_2${[SbBr$_6$](Br$_3$)} | monoclinic | P2$_1$/c | a=12.9656 b=9.3423 c=12.5920 β = 107.233° Z=2 | 1456.8 | | | |
| N-ethyl quinolinium | (N-EtQuin)[SbBr$_6$] | orthorhombic | Pnma | a=14.5122 b=11.4005 c=11.2135° Z=4 | 1855.2 | | | |
| tris(6-methylquinolinium) hexabromoantimonate(III) | (6-MeQuin)$_3$[SbBr$_6$] | | | | | | | |
| 2-methyl-1,3-benzoxazole | SbBr$_5$(boxH)$_2$ | triclinic | P1 | a=8.560 b=11.008 c=12.751 α=102.836° β=106.173° γ=93.398° | | | | |
| quinuclidinium | (C$_9$H$_7$NH)$_2$Sb$^V$Br$_9$ | monoclinic | P2$_1$/n | a=7.518 b=11.316 c=16.351 β=97.41° Z=2 | | 2.67 | red | |
| quinuclidinium | (C$_7$H$_{13}$NH)$_4$Sb$^{III}$Sb$^V$Br$_{12}$.2Br$_2$ | cubic | Fm3m | a=13.873 | 2670 | 2.45 | black | |
| 3-ammoniumpropyl imidazolium pentabromoantimonate (III) | [C$_6$H$_{13}$N$_3$]$^{2+}$[SbBr$_5$]$^{2−}$ | orthorhombic | P2$_1$2$_1$2$_1$ | 8.7120 b = 12.6608 c = 14.3498 Z = 4 | | | | |
| trihydroxonium enneabromidodiantimonate(III) | (H$_3$O)$_3$Sb$_2$Br$_9$ | monoclinic | P2$_1$/n | a = 13.4679 b = 7.6319 c = 19.1397 β = 90.240° Z=4 | 1967.3 | 3.443 | yellow | |
| hexabromoantimonic(V) acid trihydrate | HSbBr$_6$ · 3H$_2$O | monoclinic | P2$_1$/c | a = 7.110 b = 13.532 c = 12.846 β = 94.87 Z=4 | | | melt 330K | |
| tetramethylphosphonium | [(CH$_3$)$_4$P]$_3$[Sb$_2$Br$_9$] | hexagonal | P3$_1$/c | a 9.7931 c 22.697 | | | deep yellow | |
| trimethylphosphonium | [(CH$_3$)$_3$PH][SbBr$_4$] | monoclinic | P2$_1$/c | a=10.9103 b=19.8342 c=11.3617 β=100.744 Z=4 | 2415.54 | 2.851 | colourless | |
| Methyltriphenylphosphonium | (MTP)$_6$SbBr$_6$Sb$_2$Br$_9$⋅H$_2$O | trigonal | R3 | a=19.7793 c=27.2770 Z=3 | 9241 | 1.749 | | |
| Methyltriphenylphosphonium | (MTP)$_2$SbBr$_5$ | monoclinic | P2$_1$/c | a=12.7399 b=12.3833 c=26.0206 β=96.373 Z=4 | 4079.7 | 1.752 | | |
| tetraphenylphosphonium | P(C$_6$H$_5$)$_4$SbBr$_6$ | monoclinic | C2/c | a = 16.887 b = 7.357 c = 23.367 β = 93.98° Z=4 | 2896.1 | | yellow | |
| triphenyl(9-phenyl-9H-carbazol-3-yl) phosphonium antimony bromide | TPPcarzSbBr$_4$ | triclinic | P1 | a=9.77183 b=11.42472 16.15939 α=88.2199° β=80.7810° γ=71.8474°, Z = 2 | 1691.77 | 1.857 | red LED | |
| Tetraphenylphosphonium Ikosioctabromooctaantimonate(III) | (PPh$_4$)$_4$Sb$_8$Br$_{28}$ | triclinic | P1 | a=12.491 b=13.078 c=21.523 α=102.93° β=100.83° γ= 100.42°, Z = 2 | 3273 | 2.318 | | |
| Tris-Chlorobromophosphazeno-carbenium | [C(NP(Br$_{0,78}$Cl$_{0,22}$)$_3$)$_3$]SbBr$_6$ | orthorhombic | Pbca | a = 27.92 b = 11.23 c = 17.54 Z = 8 | | | | |
| | Rb$_3$Sb$_2$Br$_9$ | monoclinic | P2$_1$/n | | | | | |
| | Rb$_4$Sb$_2$Br$_{12}$ | tetragonal | I4$_1$/amd | a = 10.70 and c = 21.69 Z=8 | | 4.17 | black | |
| | Rb$_7$Sb$_3$Br$_{16}$ | orthorhombic | Cmcm | a = 23.4716 b = 13.57.89 c = 35.3947 | | | yellow | |
| | [RuNOPy$_4$Br]$_4$[Sb$_2$Br$_8$][Sb$_3$Br$_{12}$]$_2$ | monoclinic | P2$_1$/c | a=12.021 b=22.454 c=26.372 β=92.506° Z=8 | 7112 | 2.634 | light orange | |
| 1,4-bis(ammoniomethyl)cyclohexane | (C$_8$H$_{20}$N$_2$)$_2$AgMBr$_8$ | triclinic | P1 | a 8.0820 b 8.161 c 11.814 α 90.185° β 95.390° γ 90.121° | | | band gap 2.600 eV | |
| histammonium | (HIS)$_2$AgSbBr$_8$ | monoclinic | C2/c | a=11.5632 b=12.2529 c=18.694 β=94.264 Z=4 | 2641.3 | 2.754 | semiconductor; pale yellow | |
| | Cs$_3$Sb$_2$Br$_9$ | | | a=7.9165 c=9.7139 | | | yellow; orange at 300°C; perovskite | |
| | Cs$_4$Sb$_2$Br$_{12}$ | tetragonal | I4$_1$/amd | a=10.842 c=21.913 Z=2 | 2576 | | black @300K | |
| | Cs$_2$AgSbBr$_6$ | cubic | Fm3m | a = 11.1583 Z=4 | 1389.2 | 4.661 | black; bandgap 1.64 eV | |
| Benzeneethanammonium | (C$_8$NH$_{12}$)$_4$Bi$_{0.57}$Sb$_{0.43}$Br$_7$⋅H$_2$O | triclinic | P1 | a=13.0207 b=13.1304 c=13.3192 α=93.818° β=102.408° γ=108.610° Z=2 | 2085.1 | 1.971 | light green | |